These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 35860245)
1. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y Front Immunol; 2022; 13():932360. PubMed ID: 35860245 [TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427 [TBL] [Abstract][Full Text] [Related]
5. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial. Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M; Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568 [TBL] [Abstract][Full Text] [Related]
6. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial. Pochon C; Laroye C; Kimmoun A; Reppel L; Dhuyser A; Rousseau H; Gauthier M; Petitpain N; Chabot JF; Valentin S; de Carvalho Bittencourt M; Peres M; Aarnink A; Decot V; Bensoussan D; Gibot S Front Med (Lausanne); 2023; 10():1224865. PubMed ID: 37706025 [TBL] [Abstract][Full Text] [Related]
8. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979 [TBL] [Abstract][Full Text] [Related]
10. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. Ringdén O; Moll G; Gustafsson B; Sadeghi B Front Immunol; 2022; 13():839844. PubMed ID: 35371003 [TBL] [Abstract][Full Text] [Related]
11. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. Mattoli S; Schmidt M Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355 [TBL] [Abstract][Full Text] [Related]
12. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial. Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563 [TBL] [Abstract][Full Text] [Related]
19. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Can A; Coskun H Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878 [TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019. Whittaker Brown SA; Iancu-Rubin C; Aboelela A; Abrahams A; Burke E; Drummond T; Grossman F; Itescu S; Lagdameo J; Lin JY; Mark A; Levine JE; Osman K Cytotherapy; 2022 Aug; 24(8):835-840. PubMed ID: 35649958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]